 |
BioWorld-Insight-2010-07-26
Street Mulls Celgene/Abraxis: 'Consistency of Effort' Key?
Biotech Big Pharma Collaborations: Modified And Terminated Agreements, June 1 – July 22, 2010
No Abstract
Biotechs Boost Dengue Efforts Amid New Mechanistic Insights
After a 65-year absence, the dengue virus has reemerged in the continental U.S., shining a spotlight on new research into the mechanisms behind severe dengue hemorrhagic fever as well as pharma and biotech efforts to develop a dengue vaccine.